1. Home
  2. HUBC vs CANF Comparison

HUBC vs CANF Comparison

Compare HUBC & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hub Cyber Security Ltd.

HUBC

Hub Cyber Security Ltd.

HOLD

Current Price

$0.33

Market Cap

25.0M

Sector

N/A

ML Signal

HOLD

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$4.45

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUBC
CANF
Founded
2017
1994
Country
Israel
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.0M
2.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HUBC
CANF
Price
$0.33
$4.45
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9,750.00
AVG Volume (30 Days)
2.1M
549.8K
Earning Date
05-01-2026
02-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$28,966,000.00
$560,000.00
Revenue This Year
N/A
$461.72
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$3.36
52 Week High
$14.00
$46.60

Technical Indicators

Market Signals
Indicator
HUBC
CANF
Relative Strength Index (RSI) 24.97 84.84
Support Level $0.33 $3.63
Resistance Level $0.44 $4.85
Average True Range (ATR) 0.05 0.21
MACD 0.02 0.52
Stochastic Oscillator 4.60 90.07

Price Performance

Historical Comparison
HUBC
CANF

About HUBC Hub Cyber Security Ltd.

Hub Cyber Security Ltd is engaged in the development of cyber products, software, quality systems, reliability, and risk management. It operates in several countries and provides cybersecurity computing appliances as well as a wide range of cybersecurity professional services. The company has two operating segments: the Product and Technology Segment, and the Professional Services Segment. The majority of its revenue comes from the professional services segment, which provides data and cybersecurity, system security and reliability solutions, as well as related services such as consulting, planning, training, integration, and ongoing servicing of cybersecurity, risk management, system quality, reliability, and security projects, including fully managed corporate cybersecurity services.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Share on Social Networks: